Literature DB >> 27669368

Retrospective evaluation of the effect of red blood cell product age on occurrence of acute transfusion-related complications in dogs: 210 cases (2010-2012).

Christina H Maglaras1, Amie Koenig1, Deanna L Bedard1, Benjamin M Brainard1.   

Abstract

OBJECTIVE: To determine whether red blood cell (RBC) product age influences the occurrence of acute transfusion-related complications and mortality in dogs. The hypothesis was that acute transfusion-related complications and mortality would increase with age of product.
DESIGN: Retrospective study (2010-2012).
SETTING: University teaching hospital. ANIMALS: Two hundred and ten clinical canine patients.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Medical records were reviewed for dogs receiving RBC-containing products. Patient signalment; reason for transfusion; product type, dose, age, and source; pretransfusion compatibility; rate, route, and method of administration; administration of multiple transfusions; underlying disease; occurrence of transfusion-related complications (eg, fever, hemolysis, gastrointestinal distress, cardiovascular, neurologic, and respiratory complications); various hematologic parameters; and survival were recorded. Data were analyzed for association between potential risk factors and occurrence of transfusion-related complications as well as between transfusion-related complications and survival. Of 333 transfusion events in 210 patients, 84 transfusion-related complications occurred. Fever was most common (41/333), followed by hemolysis (21/333). For every additional day of product age, the odds of hemolysis increased significantly (odds ratio, 1.11; 95% confidence interval, 1.06-1.16; P < 0.0001). Transfusion-related complications when considered as a whole were associated with higher dose of product, longer duration of administration per transfusion event, and immune-mediated disease, but not with source of product or general category of anemia. Administration rate was significantly slower in patients with febrile transfusion-related complications (P < 0.0001). Product age was not associated with increased mortality.
CONCLUSIONS: Age of stored RBC products is associated with increased risk of transfusion-related hemolysis, but not with fever. Prospective clinical studies evaluating the influence of storage duration on development of in vitro versus in vivo hemolysis are warranted. © Veterinary Emergency and Critical Care Society 2016.

Entities:  

Keywords:  anemia; canine; febrile nonhemolytic transfusion reaction

Mesh:

Year:  2016        PMID: 27669368     DOI: 10.1111/vec.12530

Source DB:  PubMed          Journal:  J Vet Emerg Crit Care (San Antonio)        ISSN: 1476-4431


  5 in total

1.  Visual inspection of stored canine blood for hemolysis compared with measured plasma-free hemoglobin to assess suitability for transfusion.

Authors:  Brittany Jaeger; Miryam Reems
Journal:  Can Vet J       Date:  2018-11       Impact factor: 1.008

2.  ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs.

Authors:  James W Swann; Oliver A Garden; Claire L Fellman; Barbara Glanemann; Robert Goggs; Dana N LeVine; Andrew J Mackin; Nathaniel T Whitley
Journal:  J Vet Intern Med       Date:  2019-03-07       Impact factor: 3.333

3.  Alloimmunization in dogs after transfusion: A serial cross-match study.

Authors:  Lisa Herter; Christiane Weingart; Nina Merten; Nicole Bock; Roswitha Merle; Barbara Kohn
Journal:  J Vet Intern Med       Date:  2022-08-19       Impact factor: 3.175

4.  In vitro assessment of quality of citrate-phosphate-dextrose-adenine-1 preserved feline blood collected by a commercial closed system.

Authors:  Chiara Crestani; Annalisa Stefani; Antonio Carminato; Angelica Cro; Katia Capello; Michela Corrò; Elisa Bozzato; Franco Mutinelli; Marta Vascellari
Journal:  J Vet Intern Med       Date:  2018-04-10       Impact factor: 3.333

5.  Accuracy of point-of-care crossmatching methods and crossmatch incompatibility in critically ill dogs.

Authors:  Hayden Marshall; Shauna L Blois; Anthony C G Abrams-Ogg; Alexa M Bersenas; Kristiina Ruotsalo; Gabrielle Monteith
Journal:  J Vet Intern Med       Date:  2020-12-18       Impact factor: 3.175

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.